Abstract: A method of reducing the aggregate content in a preparation having a target protein includes contacting the preparation with an aryl anion to form a mixture and contacting the mixture with at least one electropositive solid to remove excess aryl anion.

Abstract: A method of purifying a target protein includes contacting a cell culture harvest or a protein preparation including at least one target protein with at least one fatty acid having 8 to 10 carbon atoms to form a mixture, contacting the mixture with one or more solids to form a mixture, the one or more solids comprise a cationic functional group, a metal binding functional group, or both, the metal binding functional group including a nitrogen-containing moiety selected from (1) a polyamine, (2) an imine, (3) an N-heterocycle, (4) an amino acid, (5) an N-hydroxyamide, (6), an arylamine, and combinations thereof, and separating solid materials after contacting the mixture with the one or more solids to provide a solution comprising the target protein.

Abstract: A method of reducing aggregate and product-contaminant complex content in a protein preparation including a desired protein includes (i) contacting the protein preparation with at least one solid surface comprising at least one surface-bound ligand capable of binding a metal, the surface-bound ligand being capable of binding a metal is initially substantially devoid of a metal, the operating conditions are selected to substantially prevent the binding of the desired protein to the at least one solid surface and (ii) separating the protein preparation from the surface-bound ligand, such that when more than one surface-bound ligand is present, each surface-bound ligand is independently either of the same net charge or charge neutral.

Abstract: Adsorption systems providing a capacity of at least 200 g/L for oxygen-containing mixtures, or an oxygen-nitrogen selectivity of at least 1.4:1 or at least 1:2 with an adsorbed capacity of at least 0.6 mmol/g at 4 bar and 22° C.

Abstract: The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

Abstract: A process is described for the preparation of a functionalized hybrid solid with an organic-inorganic matrix, crystallized, bearing at least one reactive group based on a triazole ring, from a hybrid solid with an organic-inorganic matrix, MOF—NH2, comprising: i/ introduction, in a polar solvent S1, of said crystallized hybrid solid MOF—NH2, of at least one organic compound Q containing a nitride function N3 and at least one intermediate reagent R containing a nitrite function NO2, ii/ reaction of said reaction mixture, iii/ introduction in the reaction mixture of at least one reagent A bearing an alkyne function or an activated cyanide function, at least one Cu-based catalyst C and at least one polar solvent S2, iv/ reaction of said reaction mixture, v/ filtration and then washing and vi/ drying of said crystallized functionalized hybrid solid.

Abstract: The present invention provides compositions and methods for cytoprotection. In particular, it provides zinc chelate compositions comprising at least one zinc ion and at least one aminothiol ligand.

Abstract: The present invention relates to a paramagnetic polynuclear metal complex having enhanced self-relaxation rate and thermodynamic stability, and more particularly, to a synthetic method of a novel DTPA-bis-amide-histidine ligand and DTPA-bis-amide-aspartic acid ligand, a novel gadolinium complex ([Gd(L)H2O]) using the ligand, and a paramagnetic polynuclear metal complex using the gadolinium complex. The paramagnetic polynuclear metal complex is able to fix three or more metals (one gadolinium and two metal ions), thereby providing more excellent self-relaxation rate than the commercially available contrast agents. Thus, it can be widely applied to an MRI contrast agent because of meeting the high self-relaxation rate required as a contrast agent of magnetic resonance imaging (MRI).

Abstract: The present invention provides compositions and methods for cytoprotection. In particular, it provides zinc chelate compositions comprising at least one zinc ion and at least one aminothiol ligand.

Abstract: The present invention is directed towards proposing ligands of formula: and is also directed towards a substrate at the surface of which is immobilized at least one unit of formula:

Abstract: The invention relates to C—H activated olefin metathesis catalyst compounds, the preparation of such compounds, and the use of such catalysts in the metathesis of olefins and olefin compounds, more particularly, the use of such catalysts in Z selective olefin metathesis reactions. In general, the catalyst compounds of the invention comprise a Group 8 metal (M), an alkylidene moiety (?CR1R2), or more generally (?(C)mCR1R2), an anionic ligand (X1), two or three neutral ligands (L1, L2, and L3) and a 2-electron anionic donor bridging moiety (Q*) that forms a chelate ring structure in conjunction with L1 and M.

Abstract: Hydrophilic self-cleaning coating compositions and methods to make and use the compositions are disclosed. The compositions include a pigment material made up of an inorganic pigment attached or linked to at least one oxidizing agent. In some embodiments, the oxidizing agent is an organic molecule covalently or non-covalently attached to the inorganic pigment. In some embodiments, the oxidizing agent is linked to the inorganic pigment by a linker moiety.

Abstract: A silica nanoparticle for diagnostic imaging that may be capable of use for X-ray CT, fluorescent imaging, or the like, and have high emission intensity. A method for producing such a silica nanoparticle for diagnostic imaging is provided. Also, a biosubstance labeling agent using the silica nanoparticle for diagnostic imaging is provided. The silica nanoparticle for diagnostic imaging encapsulates an organic fluorescent dye and a metal complex, wherein a ligand of the metal complex form a covalent bond with constituent molecules of the silica nanoparticle.

Abstract: A system and method for systematically generating potential metal-organic framework (MOFs) structures given an input library of building blocks is provided herein. One or more material properties of the potential MOFs are evaluated using computational simulations. A range of material properties (surface area, pore volume, pore size distribution, powder x-ray diffraction pattern, methane adsorption capability, and the like) can be estimated, and in doing so, illuminate unidentified structure-property relationships that may only have been recognized by taking a global view of MOF structures. In addition to identifying structure-property relationships, this systematic approach to identify the MOFs of interest is used to identify one or more MOFs that may be useful for high pressure methane storage.

Abstract: A process is described for the preparation of a functionalized hybrid solid with an organic-inorganic matrix, crystallized, bearing at least one reactive group based on a triazole ring, from a hybrid solid with an organic-inorganic matrix, MOF—NH2, comprising: i/ introduction, in a polar solvent S1, of said crystallized hybrid solid MOF—NH2, of at least one organic compound Q containing a nitride function N3 and at least one intermediate reagent R containing a nitrite function NO2, ii/ reaction of said reaction mixture, iii/ introduction in the reaction mixture of at least one reagent A bearing an alkyne function or an activated cyanide function, at least one Cu-based catalyst C and at least one polar solvent S2, iv/ reaction of said reaction mixture, v/ filtration and then washing and vi/ drying of said crystallized functionalized hybrid solid.

Abstract: The present invention provides complexes of gallium with a ligand, methods of making the complexes, methods of using the complexes and pharmaceutical gallium compositions comprising the complexes, in particular those compositions suitable for therapeutic oral administration.

Abstract: The present invention relates to a paramagnetic polynuclear metal complex having enhanced self-relaxation rate and thermodynamic stability, and more particularly, to a synthetic method of a novel DTPA-bis-amide-histidine ligand and DTPA-bis-amide-aspartic acid ligand, a novel gadolinium complex ([Gd(L)H2O]) using the ligand, and a paramagnetic polynuclear metal complex using the gadolinium complex. The paramagnetic polynuclear metal complex is able to fix three or more metals (one gadolinium and two metal ions), thereby providing more excellent self-relaxation rate than the commercially available contrast agents. Thus, it can be widely applied to an MRI contrast agent because of meeting the high self-relaxation rate required as a contrast agent of magnetic resonance imaging (MRI).

Abstract: A diagnostic agent for infectious diseases which is capable of distinguishing among different kinds of bacterial species and which allows simple and non-invasive measurement and/or imaging in a short period of time is provided; and a screening method for a therapeutic agent for infectious diseases caused by microorganisms are provided. A diagnostic agent for infectious diseases caused by nitroimidazole susceptible microorganisms, containing an imidazole derivative or a fused imidazole derivative having at least one nitro group on an imidazole ring, or a labeled form thereof as an active ingredient is provided.

Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.

Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.

Abstract: This disclosure provides novel compositions comprising an inorganic and organic compound, which provides a means for the indirect attachment of a reactive species, such as an organic reactive molecule, within a binder polymer matrix. Such compositions provide a hydrophilic nanoscale domain that is uniformly dispersed within the polymer matrix. The nanoscale domain comprises inorganic particles having a nanoscale dimension. Such compositions can enhance the performance potential of the re-active species within the polymer material. The polymer composite that results from the introduction of such reactive species into a polymer matrix provides a self-decontaminating feature. The reactive species include those that are capable of associating with a halogen to form a complex that is active in decontamination of chemical or biological agents.

Abstract: The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

Abstract: The present invention is directed towards proposing ligands of formula: and is also directed towards a substrate at the surface of which is immobilized at least one unit of formula:

Abstract: The present invention discloses certain heterocyclic complexes of metals of formula (I), especially those of manganese, which enhance the safety and efficacy of sunscreens via urocanate pathway modulation.

Abstract: The present invention relates to an organic electroluminescence device containing a light emitting metallic compound of Chemical Formula 1. In the Chemical Formula 1, M is selected from Ir, Pt, Rh, Re, and Os, and m is 2, provided that m is 1 when M is Pt.

Abstract: The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-?B dysregulation.

Abstract: Process for the preparation of modified ZnO particles in which a zinc salt and a base are mixed in a polar solvent and, if appropriate after the precipitation of a precipitation product, the polar solvent is removed and a residue is obtained, where the residue is taken up in a nonpolar solvent, surface-active substances are added, optionally further effect substances are added and then the modified ZnO particles are separated off from further by-products. Materials such as plastics, coatings or paints comprising modified ZnO particles. Methods for the incorporation of modified ZnO particles into materials, where the modified ZnO particles are incorporated into the materials in the form of dispersions or suspensions. Use of modified ZnO particles for protecting material against the effect of light, heat, oxygen or free radicals, as catalysts, for semiconductive films or cosmetic applications.

Abstract: Provided are nitroplatinum(IV) complexes containing a bidentate dicarboxylate ligand (e.g., oxalate) which maybe useful treating various forms of proliferative diseases, such as cancer. In some instances the platinum(IV) complexes are relatively stable and may be suitable for oral administration. Also provided are methods of treatment, as well as kits and unit dosages.

Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.

Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.

Abstract: The present invention discloses certain heterocyclic complexes of metals of formula (I), especially those of manganese, which enhance the safety and efficacy of sunscreens via urocanate pathway modulation.

Abstract: The present invention discloses safety and efficacy enhancement of sunscreens with certain heterocyclic base complexes of manganese via urocanate pathway modulation. The present invention also discloses a method for topical application of said complexes, which causes the reduction of topical peroxide including hydrogen peroxide, the reduction of topical inflammation including sunburn, increased sun protection of skin, the reduction of skin wrinkles, comprehensive protection from UVA, UVB, and UVC, and reduction of radiation-initiated inflammation.

Abstract: The invention relates to a method for the preparation of platinum (II) complexes, in particular dicarboxylatoplatinum (II) complexes containing a neutral bidentate ligand, such as oxaliplatin. The method includes the step of reacting a bis-dicarboxylatoplatinate (II) species with a suitable neutral bidentate ligand to form a neutral dicarboxylatoplatinum (II) complex and, if necessary, recrystallising the product to form a pure dicarboxylatoplatinum (II) complex containing a neutral bidentate ligand. The invention also relates to a method for producing a bis-dicarboxylatoplatinate (II) species, and to new platinum (II) complexes that can be made by the method of the invention.

Abstract: Compounds of the following formula: wherein X is H or substituted with with at least one X being substituted; and halo is fluorine, chlorine, bromine, iodine; and stereoisomers and conjugable analogs thereof.

Abstract: Provided is a cyclometalated transition metal complex represented by Formula 1: The cyclometalated transition metal complex contains a new ancillary ligand having a carboxylate acid or the like connected to a hetero ring, so that it can efficiently emit red light from a phosphorous material through intersystem crossing (ISC) to form triplet excitons and then metal to ligand charge transfer (MLCT). An organic light emitting device manufactured using the transition metal complex shows excellent luminous efficiency and external quantum efficiency.

Abstract: A molecule for labeling a target material is provided including two transition-metal chelates and a detectable group. The molecule has the general structural formula (I): wherein: (a) Y and Y? are each a transition metal, (b) R1 and R1? are each independently CH(COO?), CH(COOH), or absent; (c) R2 and R2? are linkers each having a length of from about 3.0 to about 20 ?; and (d) X is a detectable group. The linkers may be linear or branched, may contain aromatic moieties, and may optionally be further substituted. Methods of using the molecules of the invention as probes in detecting and analyzing target materials as well as kits including the molecule of the invention are also provided.

Abstract: Dyes and pigments present in candle wax compositions are particularly well stabilized against color fade or color change by a combination of a UV absorber and a metal compound, particularly a tin compound. The further addition of a hindered amine or antioxidant is highly beneficial.

Abstract: A method of enhancing the solubility of iron amino acid chelates and iron proteinates is disclosed. This is accomplished by mixing an effective amount of an organic acid solubilizing agent into existing iron amino acid chelates or iron proteinates. The iron amino acid chelates and iron proteinates may have a ligand to metal molar ratio from about 1:1 to 4:1, preferably 2:1 to 3:1.

Abstract: The present invention is directed to a method of determining the ratio of the concentration or amounts of two or more chemical compounds and/or biopolymers, or of the relative amounts of sub-populations of closely structurally related compounds, in a multi-component mixture, extract, system, and the like using an analytical physicochemical process. The method is based on distribution of the components of the mixture (system, extract, etc.) between two or more immiscible phases and the subsequent determination of the total amounts (concentrations) of biopolymers (chemical compounds) or of the amounts (concentrations) of one or more component(s) or sub-populations of the system in the phases. The ratio between these concentrations is defined therein as the partition coefficient. The partition coefficient is used as a measure of the ratio of the amounts of two or more biopolymers (chemical compounds) or their sub-populations in a multi-component mixture (extract, system, etc.

Abstract: The object of the present invention is to provide a novel compound which has various biological activities and is useful for medical and animal drugs. The present invention provides a compound represented by the formula: ##STR1## wherein R.sup.1 is COOR.sup.4, CONR.sup.5 R.sup.6, CO--R.sup.7 --OR or CH.sub.2 OR.sup.8 ; R.sup.2 is hydrogen atom, alkyl, aralkyl, heteroaryl, heteroarylalkyl, COR.sup.13, COOR.sup.14, CONR.sup.15 R.sup.16 ; R.sup.3 is hydrogen atom or OR.sup.3 ; a broken line ( - - - ) represents the presence of a double bond when R.sup.3 is oxygen atom and the absence of a double bond when R.sup.3 is OR.sup.3, or a salt or metal chelete thereof.

Abstract: The present invention relates to the treatment of tumors with a novel water soluble trans-platinum coordination compound having the general structural formula [PtBX.sub.m (NR*.sub.3)] where B is a planar, heterocyclic ring containing at least one nitrogen atom, and a pendant chelating group; and X is an anionic ligand; and R* is hydrogen or a lower alkyl.

Abstract: The invention is a compound of the formula: ##STR1## wherein M is a bivalent or trivalent metal ion, and X is OH or O.sup..crclbar.. The above compound of the present invention is useful for prevention or treatment of mycoplasmosis.

Abstract: Compounds of general Formula I ##STR1## wherein R.sup.3 is a saturated, unsaturated, straight- or branched-chain or cyclic aliphatic hydrocarbon residue of up to 16 carbon atoms or, if R.sup.4 is a hydrogen atom, a cycloalkyl group or an aryl or aralkyl group optionally substituted by one or several C.sub.1 -C.sub.6 -dialkylamino groups or by one or several C.sub.1 -C.sub.6 -alkoxy groups,R.sup.4 is a hydrogen atom, a saturated, unsaturated, straight- or branched-chain or cyclic hydrocarbon residue of up to 16 carbon atoms, orR.sup.3 and R.sup.4 jointly mean a saturated or unsaturated 5- or 6-membered ring optionally substituted or containing an O, S, N atom or oxo substituent, and Y is COOX or CONR.sub.3 R.sub.4,are valuable complexing agents, complexes or complex salts, e.g., for use as NMR or X-ray diagnostic image-enhancement agents or radioactive diagnostic agents.

Abstract: Ruthenium complexes with a chiral ligand of the general formula: ##STR1## are used for the enantioselective transfer hydrogenation of prochiral ketones.

Abstract: Novel magnetic resonance imaging agents comprise complexes of paramagnetic ions with hydrazide derivatives of polyaminocarboxylic acid chelating agents. These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions. A novel method of performing an NMR diagnostic procedure involves administering to a warm-blooded animal an effective amount of a complex as described above and then exposing the warm-blooded animal to an NMR imaging procedure, thereby imaging at least a portion of the body of the warm-blooded animal.

Abstract: Compounds of formula (I): ##STR1## in which: A and B are separately monoamines or together diamines; and Z is a group of formula (II) or (III): ##STR2## (in which R.sup.1, R.sup.2 and R.sup.7 are various organic groups, n is 0, 1 or 2 and X is a direct carbon-carbon bond or lower alkylene) show valuable anti-tumor activity and may be prepared by reacting an amine-platinum complex with a compound providing the group represented by Z.

Abstract: An antipruritic agent comprising a zinc-amino acid complex, and an antipruritic composition containing said antipruritic agent at a concentration of 2.6.times.10.sup.-3 to 2.6.times.10.sup.-1 M.

Abstract: .beta.-hydroxyhistidine, 4-(1-hydroxy-1-alkyl)imidazole or derivatives thereof can be used as a bidentate ligand in the chelation of iron(III), Al(III), Cr(III), Ga(III) and the actinides(IV), such as plutonium 238. .beta.-hydroxyhistidine is found in a pyoverdine-type siderophore produced by Pseudomonas fluorescens 244.

Abstract: Metallated compounds can be used to extract or precipitate proteins from solution. The compounds can be polymers, such as polyalkylene glycols, which can be mono- or bimetallated or smaller bis-metal chelates, such as ethylenebis(oxyethylenenitrilo)tetraacetic acid. The monometallated polymers are preferred in the extraction process whereas the bimetallated compounds are preferred in the precipitation process. In addition, new PEG compounds which are capable of chelating a variety of metals are described. Both mono- and bi-metallated forms are set forth. The new metallated compounds are very effective in extracting or precipitating proteins from solution.

Abstract: Antitumor acting platinum(II or IV) complexes of the general formula ##STR1## where B represents a phenyl-C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted in the phenyl nucleus by the radical R.sub.1 and R.sub.1 is hydrogen, halogen, trihalogen methyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or C.sub.2 -C.sub.6 -alkanoyloxy or where B together with the structural part H.sub.2 N-CR.sub.2 < forms a tetrahydroisoquinoline radical, if B contains benzyl and R.sub.2 hydrogen and the benzyl radical in the 2-position contains the CH.sub.2 -radical or where B together with the structural part --CR.sub.2 < represents a tetrahydronaphthyl radical in which one CH.sub.2 group is optionally replaced by oxygen, or where B together with the structural part --CR.sub.2 < represents a decahydronaphthyl radical or an indanyl radical; R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 -alkyl, phenyl or phenyl-C.sub.1 -C.sub.4 -alkyl, it also being possible for the phenyl ring of this group R.